57489-77-7

Basic information

• Product Name: 5,7-DICHLOROPYRAZOLO[1,5-A]PYRIMIDINE
• Synonyms: 5,7-DICHLOROPYRAZOLO[1,5-A]PYRIMIDINE;7-dichloropyrazolo[1;Pyrazolo[1,5-a]pyrimidine, 5,7-dichloro-
• CAS NO: 57489-77-7
• Molecular Formula: C₆H₃Cl₂N₃
• Molecular Weight: 188.01
• Product Categories: CHIRAL CHEMICALS;Heterocycle-Pyrimidine series
• Mol File: 57489-77-7.mol
• Article Data: 36

Chemical Properties

• Melting Point: 68-71 °C(Solv: ethanol (64-17-5))
• Appearance: /
• Density: 1.696 g/cm³
• Refractive Index: 1.733
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: -1.68±0.30(Predicted)
• CAS DataBase Reference: 5,7-DICHLOROPYRAZOLO[1,5-A]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5,7-DICHLOROPYRAZOLO[1,5-A]PYRIMIDINE(57489-77-7)
• EPA Substance Registry System: 5,7-DICHLOROPYRAZOLO[1,5-A]PYRIMIDINE(57489-77-7)

Safety Data

• Hazardous Substances Data: 57489-77-7(Hazardous Substances Data)

Usage

General Description

5,7-Dichloropyrazolo[1,5-a]pyrimidine is a chemical compound with the molecular formula C5H2Cl2N4. It is a heterocyclic compound that contains a pyrazole ring fused to a pyrimidine ring, with chlorine atoms attached at the 5 and 7 positions. 5,7-Dichloropyrazolo[1,5-a]pyrimidine has been studied for its potential biological activities, including as a kinase inhibitor. It is also used in the synthesis of other organic compounds. 5,7-Dichloropyrazolo[1,5-a]pyrimidine is a versatile building block in organic synthesis and is of interest to researchers in various fields such as medicinal chemistry and pharmaceuticals.

InChI:InChI=1/C6H3Cl2N3/c7-4-3-5(8)11-6(10-4)1-2-9-11/h1-3H

Upstream product

• 57489-70-0 5,7-dihydroxypyrazolo[1,5-a]pyrimidine 
• 124-40-3 dimethyl amine 
• 121-69-7 N,N-dimethyl-aniline 
• 1820-80-0 3-aminopyrazole 
• 105-53-3 diethyl malonate 
• 672323-32-9 pyrazolo[1,5-a]pyrimidine-5,7(4H,6H)-dione 

Downstream Products

• 114040-06-1 3-bromo-5,7-dichloropyrazolo[1,5-a]pyrimidine 
• 1190115-62-8 5-chloro-N-(2-(isopropylsulfonyl)phenyl)pyrazolo[1,5-a] pyrimidin-7-amine 
• 761453-91-2 C₁₃H₁₁ClN₄ 
• 1232220-27-7 N-(3-methyl-benzylidene)-N'-(7-morpholin-4-yl-pyrazolo-[1,5-a]pyrimidin-5-yl)-hydrazine 
• 1232220-31-3 N-(3-bromo-7-morpholin-4-yl-pyrazolo[1,5-a]pyrimidin-5-yl)-N'-(3-methyl-benzylidene)-hydrazine 
• 220456-74-6 5-chloro-7-<<2'-cyanobiphenyl-4-yl>methyl>pyrazolo<1,5-a>pyrimidine 
• 99898-84-7 5-chloropyrazolo<1,5-a>pyrimidin-7-one 

Relevant articles and documents

TYK2 PSEUDOKINASE LIGANDS

Described herein are TYK2 pseudokinase ligands and methods of utilizing TYK2 pseudokinase ligands in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

Synthesis of two novel pyrazolo[1,5-a]pyrimidine compounds with antibacterial activity and biophysical insights into their interactions with plasma protein

Two novel water-soluble pyrazolo[1,5-a]pyrimidine derivatives, 5-chloro-7-(4-methyl-piperazin ?1-yl)-pyrazolo[1,5-a]pyrimidine (CMPS) and N′-(5-chloro-pyrazolo[1,5-a]pyrimidin-7-yl)-N,N-dimethyl -propane-1,3-diamine (NCPS), were synthesized and characterized with antibacterial activity. Then, the interactions of these compounds with bovine serum albumin (BSA) were studied by fluorescence, time-resolved fluorescence, circular dichroism (CD) spectroscopy and molecular docking. The results indicate that both CMPS and NCPS could effectively quench the intrinsic fluorescence of BSA via a static quenching process. The energy transfer from BSA to CMPS and NCPS may occur with high probability. Both CMPS and NCPS bind in the site I of BSA. The hydrophobic force and hydrogen bonds play major roles in the complex formation. Binding constants for both systems show that the affinity of CMPS binding to BSA is stronger than that of NCPS. The results of three-dimensional fluorescence and CD spectra reveal that the binding of CMPS and NCPS to BSA can induce conformational changes of BSA, and the influence of CMPS is slightly stronger than that of NCPS.

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.